Apitegromab
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Spinal Muscular Atrophy
Conditions
Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations, Anti-myostatin
Trial Timeline
Apr 17, 2023 → May 2, 2029
NCT ID
NCT05626855About Apitegromab
Apitegromab is a phase 3 stage product being developed by Scholar Rock Holding for Spinal Muscular Atrophy. The current trial status is active. This product is registered under clinical trial identifier NCT05626855. Target conditions include Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2.
What happened to similar drugs?
7 of 20 similar drugs in Spinal Muscular Atrophy were approved
Approved (7) Terminated (1) Active (12)
Hype Score Breakdown
Clinical
17
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06877689 | Pre-clinical | Active |
| NCT05626855 | Phase 3 | Active |
Competing Products
20 competing products in Spinal Muscular Atrophy